Pemafibrate: First Global Approval
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Pemafibrate (Parmodia®) is a novel, highly selective peroxisome proliferator-activated receptor (PPAR)-α modulator (SPPARM). It acts by binding to PPAR-α and regulating the expression of target genes that modulate lipid metabolism, thereby decreasing plasma triglyceride levels and increasing high-density lipoprotein cholesterol levels. Developed by Kowa Company, Ltd., oral pemafibrate has been approved in Japan for the treatment of hyperlipidaemia (including familial hyperlipidaemia). This article summarizes the milestones in the development of pemafibrate leading to this first global approval for hyperlipidaemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Excretion rate of unmetabolized pemafibrate into urine is < 0.5%, and almost all the metabolized compounds excreted in the urine have no PPARα agonist activity.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [92]
In the citing paper
“The main metabolites of pemafibrate in plasma are benzyl oxidized oxidant and a mixture of glucuronic acid conjugate and N-dealkylated dicarboxylic acid [92].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [92]
Citations
Cites
Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208
Hennuyer, N., Duplan, I., Paquet, C., Vanhoutte, J., Woitrain, E., Touche, V., Colin, S., Vallez, E., Lestavel, S., Lefebvre, P., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.003 · Cited by 132
Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.032 · Cited by 124
Raza-Iqbal, S., Tanaka, T., Anai, M., Inagaki, T., Matsumura, Y., Ikeda, K., Taguchi, A., Gonzalez, F. J., Sakai, J., & Kodama, T. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.28720 · Cited by 100
Takei, K., Han, S., Murayama, Y., Satoh, A., Oikawa, F., Ohno, H., Osaki, Y., Matsuzaka, T., Sekiya, M., IWASAKI, H. O., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12621 · Cited by 50
Sairyo, M., Kobayashi, T., Masuda, D., Kanno, K., Zhu, Y., Okada, T., Koseki, M., Ohama, T., Nishida, M., Sakata, Y., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.39693 · Cited by 47
Takei, K., Nakagawa, Y., Wang, Y., Han, S.-I., Satoh, A., Sekiya, M., Matsuzaka, T., & Shimano, H. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2017.02.003 · Cited by 43
Arai, H., Ishibashi, S., Yamashita, S., Araki, E., Yokote, K., Suganami, H., & Kodama, T. (2015) · Circulation · doi:10.1161/circ.132.suppl_3.13374 · Cited by 6
Yamashita, S., Ishibashi, S., Arai, H., Araki, E., Yokote, K., & Kodama, T. (2013) · Circulation · Cited by 5
Research works printed but not linked: 5
- Yamashita S, Ishibashi S, Arai H, et al. Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on postprandial hyperlipidemia in dyslipidemic patients: a randomized cross-over study [abstract no. P5891]. Eur Heart J. 2016;37(Suppl 1):1204.
- Yamashita S, Ishibashi S, Arai H, et al. Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on cholesterol efflux from macrophages in dyslipidemic patients [abstract no. P5982]. Eur Heart J. 2015;36(Suppl. 1):1047–8.
- Araki E, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARα modulator (SPPARMα), on lipid and glucose metabolism in fasting and postprandial states in type 2 diabetic patients with dyslipidaemia [abstract no. 1112]. Diabetologia. 2016;59(Suppl. 1):S531.
- Kastelein JJP, Senko Y, Hounslow N, et al. K-877, a selective PPAR alpha modulator (SPPARM alpha), ameliorates dyslipidaemia in patients with well-controlled LDL cholesterol levels on statin therapy, without increases in serum creatinine [abstract no. P5983]. Eur Heart J. 2015;36(Suppl. 1):1048.
- Kastelein JJP, Senko Y, Hounslow N, et al. K-877, a selective PPAR alpha modulator (SPPARM alpha), improves dyslipidaemia in statin-treated patients with type 2 diabetes mellitus [abstract no. P5985]. Eur Heart J. 2015;36(Suppl. 1):1048.
Cited by
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1589 · Cited by 164
“fenofibrate and gemfibrozil are eliminated via kidneys (26,28).”
Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.44412 · Cited by 136
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 96
Metadata
- Authors
- Blair, H. A.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Blair, Hannah A.
- Venue
- Drugs
- Published
- 2017-09-19
- Volume
- 77
- Issue
- 16
- Pages
- 1805-1810
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2755428798
- Cited by
- 54
- References
- 9
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 4 · 2023: 7 · 2022: 7 · 2021: 7 · 2020: 3 · 2019: 8 · 2018: 4 · 2017: 1
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- pemafibrate, hyperlipidemia, lipid metabolism, triglyceride lowering, HDL cholesterol, drug development, regulatory approval
- MeSH terms
- Benzoxazoles, Butyrates, Humans, Hyperlipidemias, Lipoproteins, HDL, Cholesterol, HDL, Protein Binding, Drug Approval, PPAR alpha, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pemafibrate: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-017-0818-x
- The paper
- Blair, H. A. (2017). Pemafibrate: First Global Approval. Drugs. https://doi.org/10.1007/s40265-017-0818-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.